Related Experiment Videos
Discordant regulation of transforming growth factor-beta receptors by prostaglandin E2
A Fine1, M P Panchenko, B D Smith
1Pulmonary Center, Boston University School of Medicine, MA 02118.
Abstract:
The effect of PGE2 on TGF-beta receptor binding was assessed for both signaling (type I and type II) and non-signaling (type III) TGF-beta receptors. We found in cross-linking studies that PGE2 treatment (24 h) decreased binding of TGF-beta to the type I and type II receptors by approx. 50% and markedly increased binding of TGF-beta to type III receptors nearly 10-fold. Northern analyses indicated that PGE2 decreased type I receptor mRNA levels by approximately 30-50%, decreased type II receptor mRNA levels by approximately 60%, and markedly increased type III receptor mRNA levels. Coincubation with cycloheximide partially blocked the PGE2-induced inhibition of type II receptor mRNA. In contrast, cycloheximide minimally affected PGE2-induced type III receptor mRNA levels. Activation of protein kinase C by phorbol esters had no apparent effect on TGF-beta receptor mRNA levels. Our data suggest that alterations in TGF-beta receptor expression could modify the response of tissues to TGF-beta during injury.
Insights
Prostaglandin E2 (PGE2) alters transforming growth factor-beta (TGF-beta) receptor binding and mRNA levels. PGE2 decreases TGF-beta binding to type I and II receptors while increasing it for type III receptors.
Area of Science:
- Molecular biology
- Cell signaling
- Biochemistry
Background:
- Transforming growth factor-beta (TGF-beta) is a crucial cytokine regulating cell growth, differentiation, and immune responses.
- TGF-beta exerts its effects by binding to specific cell surface receptors, including signaling (Type I and II) and non-signaling (Type III) receptors.
- Prostaglandin E2 (PGE2) is a lipid mediator involved in inflammation and tissue repair, with known roles in modulating cellular responses.
Purpose of the Study:
- To investigate the impact of PGE2 on the binding affinity of TGF-beta to its various receptor types.
- To determine how PGE2 influences the expression levels of TGF-beta receptor mRNAs.
- To elucidate the molecular mechanisms underlying PGE2-mediated changes in TGF-beta receptor dynamics.
Main Methods:
- Cross-linking studies were employed to quantify TGF-beta binding to Type I, II, and III receptors following PGE2 treatment.
- Northern blot analysis was used to assess changes in the mRNA levels of TGF-beta receptors.
- Experiments involving cycloheximide were conducted to explore the role of protein synthesis in PGE2-induced mRNA alterations.
- Phorbol ester treatment was used to investigate the involvement of protein kinase C signaling.
Main Results:
- PGE2 treatment significantly decreased TGF-beta binding to Type I and II receptors by approximately 50%.
- PGE2 markedly increased TGF-beta binding to Type III receptors by nearly 10-fold.
- PGE2 reduced Type I and II receptor mRNA levels by 30-60% while substantially increasing Type III receptor mRNA levels.
- Cycloheximide partially inhibited the PGE2-induced decrease in Type II receptor mRNA but had minimal effect on Type III receptor mRNA levels.
Conclusions:
- PGE2 significantly modulates TGF-beta receptor binding and expression, shifting the balance towards Type III receptors.
- These alterations in TGF-beta receptor dynamics, influenced by PGE2, may play a role in modifying tissue responses to TGF-beta during injury and repair processes.
- The differential regulation of receptor subtypes suggests a complex interplay between inflammatory mediators like PGE2 and TGF-beta signaling pathways.